Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 27, 2010

Qiagen and Roche Bury the Hatchet on Dispute over DxS TheraScreen Assay Distribution

  • Qiagen and Roche Molecular Systems have managed to settle a dispute about distribution rights to DxS’ TheraScreen companion diagnostics before the claims filed by the two companies against each other actually came to court. DxS, which develops and markets the TheraScreen diagnostics, was acquired by Qiagen in a roughly $95 million cash deal back in September 2009.

    Under the terms of the settlement, Roche has maintained its existing distribution rights to DxS’ TheraScreen KRAS and TheraScreen EGFR assays. It also retains rights to distribute future versions of these products under certain conditions. Additionally, the firm has been granted an option to extend the term of the distribution agreement for the TheraScreen EGFR assay, beyond 2011 when it currently ends.

    Qiagen, in return, retains rights to distribute the KRAS and EGFR assays under its own label. It also has exclusive distribution rights to all other assays including future assays developed and manufactured by its DxS subsidiary.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »